HC Wainwright Reaffirms “Buy” Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $150.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 50.42% from the company’s previous close.

A number of other research firms also recently weighed in on BNTX. Canaccord Genuity Group restated a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a report on Thursday. HSBC increased their price target on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. TD Cowen reduced their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Finally, The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the stock from $90.00 to $137.00 in a report on Friday, November 8th. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, BioNTech has an average rating of “Moderate Buy” and an average price target of $137.54.

BioNTech Stock Performance

NASDAQ:BNTX opened at $99.72 on Monday. The stock’s 50-day moving average is $113.54 and its 200-day moving average is $97.29. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock has a market cap of $23.91 billion, a P/E ratio of -47.49 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 EPS. Equities research analysts anticipate that BioNTech will post -3.68 earnings per share for the current year.

Institutional Trading of BioNTech

Hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after acquiring an additional 111 shares in the last quarter. Covestor Ltd boosted its position in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the period. Capital International Sarl increased its stake in BioNTech by 1.3% during the 1st quarter. Capital International Sarl now owns 24,058 shares of the company’s stock valued at $2,219,000 after purchasing an additional 310 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.